These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 18582211)

  • 41. Characterization of three novel monoclonal antibodies against hepatitis C virus core protein.
    Moradpour D; Wakita T; Tokushige K; Carlson RI; Krawczynski K; Wands JR
    J Med Virol; 1996 Mar; 48(3):234-41. PubMed ID: 8801283
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of hepatitis C virus NS3-mediated cell transformation by recombinant intracellular antibodies.
    Zemel R; Berdichevsky Y; Bachmatov L; Benhar I; Tur-Kaspa R
    J Hepatol; 2004 Jun; 40(6):1000-7. PubMed ID: 15158342
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination.
    Chen A; Ahlén G; Brenndörfer ED; Brass A; Holmström F; Chen M; Söderholm J; Milich DR; Frelin L; Sällberg M
    J Immunol; 2011 May; 186(9):5107-18. PubMed ID: 21430225
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multiple full-length NS3 molecules are required for optimal unwinding of oligonucleotide DNA in vitro.
    Tackett AJ; Chen Y; Cameron CE; Raney KD
    J Biol Chem; 2005 Mar; 280(11):10797-806. PubMed ID: 15634684
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood.
    Beld M; Penning M; van Putten M; Lukashov V; van den Hoek A; McMorrow M; Goudsmit J
    Hepatology; 1999 Apr; 29(4):1288-98. PubMed ID: 10094977
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis C virus nonstructural protein NS3 binds to Sm-D1, a small nuclear ribonucleoprotein associated with autoimmune disease.
    Iwai A; Hasumura Y; Nojima T; Takegami T
    Microbiol Immunol; 2003; 47(8):601-11. PubMed ID: 14524621
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of ATPase activity of a hepatitis C virus NS3 helicase domain, and analysis involving mercuric reagents.
    Kyono K; Miyashiro M; Taguchi I
    J Biochem; 2003 Oct; 134(4):505-11. PubMed ID: 14607976
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Preparation, characterization and application of monoclonal antibody against RecQ helicase].
    Zhang R; Jia T; Lian F; Liu J; Zhou M
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Feb; 34(2):169-174. PubMed ID: 29673459
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development and characterization of murine monoclonal antibodies specific for dissimilatoric copper nitrite reductase.
    Metz S; Hartmann A; Schloter M
    Hybrid Hybridomics; 2002 Oct; 21(5):351-7. PubMed ID: 12470477
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Establishment of anti-HCV NS5 alpha McAb hybridoma cell lines and its application on clinical immunohistochemical diagnosis].
    Gao J; Ji H; Lang Z
    Zhonghua Yi Xue Za Zhi; 1996 Aug; 76(8):585-7. PubMed ID: 9275470
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of protease and helicase mutations on HCV NS3 activity.
    Eisa ZM
    Saudi J Biol Sci; 2011 Apr; 18(2):195-200. PubMed ID: 23961124
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cloning and expression of NS3 helicase fragment of hepatitis C virus and the study of its immunoreactivity in HCV infected patients.
    Sadri M; Farajollahi MM; Sharifi Z
    Iran J Basic Med Sci; 2015 Feb; 18(2):159-63. PubMed ID: 25810890
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of hepatitis C virus nonstructural protein NS3 on proliferation and MAPK phosphorylation of normal hepatocyte line.
    Feng DY; Sun Y; Cheng RX; Ouyang XM; Zheng H
    World J Gastroenterol; 2005 Apr; 11(14):2157-61. PubMed ID: 15810084
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C.
    Belon CA; Frick DN
    Future Virol; 2009 May; 4(3):277-293. PubMed ID: 20161209
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The NS3 protein of bluetongue virus exhibits viroporin-like properties.
    Han Z; Harty RN
    J Biol Chem; 2004 Oct; 279(41):43092-7. PubMed ID: 15292261
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Endogenous hepatitis C virus homolog fragments in European rabbit and hare genomes replicate in cell culture.
    Silva E; Marques S; Osório H; Carvalheira J; Thompson G
    PLoS One; 2012; 7(11):e49820. PubMed ID: 23185448
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells.
    Sakamuro D; Furukawa T; Takegami T
    J Virol; 1995 Jun; 69(6):3893-6. PubMed ID: 7745741
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Letter to the editor: Sequence-specific 1H, 15N and 13C resonance assignments for an engineered arginine-rich domain of the hepatitis C virus NS3 RNA helicase.
    Liu D; Wyss DF
    J Biomol NMR; 2000 Nov; 18(3):279-80. PubMed ID: 11142518
    [No Abstract]   [Full Text] [Related]  

  • 59. Molecular docking analysis of fluoroquinolones and other natural and synthetic compounds with the HCV NS3 helicase.
    Ul Haq A; Sheikh A; Naeem S; Abidi SH
    Bioinformation; 2022; 18(3):147-154. PubMed ID: 36518146
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.